Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-pyrazinamine, 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-
2. 3-(3-(4-((methylamino)methyl)phenyl)-1,2-oxazol-5-yl)-5-(4-(propane-2-sulfonyl)phenyl)pyrazin-2-amine
3. Ve-822
4. Vx-970
1. Ve-822
2. 1232416-25-9
3. Vx-970
4. Ve822
5. Vx970
6. Ve 822
7. Berzosertib [usan]
8. Ve-822 (vx-970)
9. L423prv3v3
10. M6620
11. 2-pyrazinamine, 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-
12. 3-(3-{4-[(methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine
13. 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine
14. 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine
15. M-6620
16. 3-(3-(4-((methylamino)methyl)phenyl)-1,2-oxazol-5-yl)-5-(4-(propane-2-sulfonyl)phenyl)pyrazin-2-amine
17. Bdbm50226746
18. 2-pyrazinamine, 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-
19. 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine
20. 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine.
21. Unii-l423prv3v3
22. 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-2-pyrazinamine
23. Vx-970;berzosertib
24. Berzosertib [inn]
25. Berzosertib (usan/inn)
26. Berzosertib (ve-822)
27. Agn-pc-0cxkb3
28. Berzosertib [who-dd]
29. Gtpl8003
30. Schembl3061890
31. Chembl3989870
32. Ex-a529
33. Chebi:131166
34. Bdbm350085
35. Dtxsid601025940
36. Hms3653c05
37. Hms3747i11
38. Bcp07948
39. Mfcd27976794
40. Nsc777718
41. S7102
42. Us10208027, Compound Ii-1
43. Us10208027, Compound Ii-2
44. Us10208027, Compound Ii-3
45. Us10208027, Compound Ii-4
46. Vx 970
47. Zinc96170459
48. Akos025404905
49. Ccg-264673
50. Cs-1861
51. Db11794
52. Nsc-777718
53. Sb17265
54. Ncgc00386313-07
55. Ac-32951
56. As-17041
57. Da-46989
58. Hy-13902
59. Ft-0700136
60. Sw220202-1
61. A13289
62. D11148
63. A857986
64. Q27089129
65. 5-(4-isopropylsulfonylphenyl)-3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine
66. Synthesis Of 3-[3-[4-[dideuterio(methylamino)methyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine
| Molecular Weight | 463.6 g/mol |
|---|---|
| Molecular Formula | C24H25N5O3S |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 463.16781085 g/mol |
| Monoisotopic Mass | 463.16781085 g/mol |
| Topological Polar Surface Area | 132 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 714 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Berzosertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Berzosertib, including repackagers and relabelers. The FDA regulates Berzosertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Berzosertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Berzosertib supplier is an individual or a company that provides Berzosertib active pharmaceutical ingredient (API) or Berzosertib finished formulations upon request. The Berzosertib suppliers may include Berzosertib API manufacturers, exporters, distributors and traders.
Berzosertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Berzosertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Berzosertib GMP manufacturer or Berzosertib GMP API supplier for your needs.
A Berzosertib CoA (Certificate of Analysis) is a formal document that attests to Berzosertib's compliance with Berzosertib specifications and serves as a tool for batch-level quality control.
Berzosertib CoA mostly includes findings from lab analyses of a specific batch. For each Berzosertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Berzosertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Berzosertib EP), Berzosertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Berzosertib USP).
LOOKING FOR A SUPPLIER?
